Impacting Therapeutic Inertia
Despite advancements in diabetes and cardiometabolic care, therapeutic targets are not being met. One reason for this is therapeutic inertia, defined as the failure to advance or de-intensify pharmaceutical therapy and other interventions known to prevent
negative outcomes. Therapeutic inertia can prevent an individual from reaching target glucose levels and other important individualized goals. However, when diabetes care and education specialists are included in care, they can directly influence
patient engagement and ultimately reduce the risk for negative outcomes.
Podcast: Reducing Therapeutic Inertia
At the center of the care model, diabetes care and education specialists are a critical solution to reducing therapeutic inertia. In this episode, Andrew Bzowyckyj, PharmD, BCPS, CDCES and Shannon Knapp, BSN, RN, CDCES join us to discuss how they have leveraged their work with stakeholders to impact this growing problem.
- Overcoming Therapeutic Inertia Initiative, featuring resources for healthcare professionals from an alliance led by the American Diabetes Association and supported by ADCES, the American Academy of Physician Associates, the American Association of Nurse Practitioners, the American College of Osteopathic Family Physicians, the American Pharmacists Association, the American Society of Health-System Pharmacists and the American Medical Group Association.
- Access a resource on reviewing technology needs with clients and other technology integration tools from ADCES.
Journal Articles & Other Publications